Cargando…

Protection of IFNAR (−/−) Mice against Bluetongue Virus Serotype 8, by Heterologous (DNA/rMVA) and Homologous (rMVA/rMVA) Vaccination, Expressing Outer-Capsid Protein VP2

The protective efficacy of recombinant vaccines expressing serotype 8 bluetongue virus (BTV-8) capsid proteins was tested in a mouse model. The recombinant vaccines comprised plasmid DNA or Modified Vaccinia Ankara viruses encoding BTV VP2, VP5 or VP7 proteins. These constructs were administered alo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jabbar, Tamara Kusay, Calvo-Pinilla, Eva, Mateos, Francisco, Gubbins, Simon, Bin-Tarif, Abdelghani, Bachanek-Bankowska, Katarzyna, Alpar, Oya, Ortego, Javier, Takamatsu, Haru-Hisa, Mertens, Peter Paul Clement, Castillo-Olivares, Javier
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3625202/ https://www.ncbi.nlm.nih.gov/pubmed/23593251 http://dx.doi.org/10.1371/journal.pone.0060574

Ejemplares similares

Significant protection from infection and AIDS progression after gastrointestinal and oral vaccinations, respectively, with a SIV DNA/rMVA vaccine
por: Aldovini, A, et al.
Publicado: (2012)

Heterologous Prime-Boost Regimens Using rAd35 and rMVA Vectors Elicit Stronger Cellular Immune Responses to HIV Proteins Than Homologous Regimens
por: Ratto-Kim, Silvia, et al.
Publicado: (2012)

OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial
por: Currier, JR, et al.
Publicado: (2009)

Detection of broad functional gag-specific CD4+ T cell responses in HIV-1-infected subjects following therapeutic immunization with rMVA expressing an HIV-1 gag immunogen
por: Ondondo, Beatrice, et al.
Publicado: (2006)

A Modified Vaccinia Ankara Virus (MVA) Vaccine Expressing African Horse Sickness Virus (AHSV) VP2 Protects Against AHSV Challenge in an IFNAR −/− Mouse Model
por: Castillo-Olivares, Javier, et al.
Publicado: (2011)

Co-expressing GP5 and M proteins under different promoters in recombinant modified vaccinia virus ankara (rMVA)-based vaccine vector enhanced the humoral and cellular immune responses of porcine reproductive and respiratory syndrome virus (PRRSV)
por: Zheng, Qisheng, et al.
Publicado: (2007)

The immunogenicity of recombinant vaccines based on modified Vaccinia Ankara (MVA) viruses expressing African horse sickness virus VP2 antigens depends on the levels of expressed VP2 protein delivered to the host
por: Calvo-Pinilla, Eva, et al.
Publicado: (2018)

Vaccination of horses with a recombinant modified vaccinia Ankara virus (MVA) expressing African horse sickness (AHS) virus major capsid protein VP2 provides complete clinical protection against challenge
por: Alberca, Berta, et al.
Publicado: (2014)

Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines
por: Meseda, Clement A., et al.
Publicado: (2016)

The 90 MVA transformer
Publicado: (1974)

Selection of recombinant MVA by rescue of the essential D4R gene
por: Ricci, Patricia S, et al.
Publicado: (2011)

An MVA Approach to Missing $E_T$
por: Herwig, Theodor Christian
Publicado: (2013)

Ciliopathy in PCS (MVA) syndrome
por: Miyamoto, Tatsuo, et al.
Publicado: (2015)

Mechanism of pyocyanin abolishment caused by mvaT mvaU double knockout in Pseudomonas aeruginosa PAO1
por: Dong, Limin, et al.
Publicado: (2019)

The Future of Smallpox Vaccination: is MVA the key?
por: Slifka, Mark K
Publicado: (2005)

DNA/MVA Vaccines for HIV/AIDS
por: Iyer, Smita S., et al.
Publicado: (2014)

Pathological Characterization Of IFNAR(-/-) Mice Infected With Bluetongue Virus Serotype 4
por: Marín-López, Alejandro, et al.
Publicado: (2016)

Installing a 220 MVA power transformer
por: Ordan, Julien Marius, et al.
Publicado: (2018)

Installation of a 70 MVA Power Transformer
por: Balle, Christoph
Publicado: (2013)

Heterologous Combination of ChAdOx1 and MVA Vectors Expressing Protein NS1 as Vaccination Strategy to Induce Durable and Cross-Protective CD8+ T Cell Immunity to Bluetongue Virus
por: Utrilla-Trigo, Sergio, et al.
Publicado: (2020)

Reduced Life- and Healthspan in Mice Carrying a Mono-Allelic BubR1 MVA Mutation
por: Wijshake, Tobias, et al.
Publicado: (2012)

P19-58 LB. Comparison of the immunogenicity in humans and rhesus macaques of vaccines consisting of DNA priming and MVA boosting and MVA priming and boosting
por: Robinson, HL, et al.
Publicado: (2009)

Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
por: Rollier, Christine S., et al.
Publicado: (2016)

MVA85A vaccine to enhance BCG for preventing tuberculosis
por: Kashangura, Rufaro, et al.
Publicado: (2019)

High-cell-density cultivations to increase MVA virus production
por: Vázquez-Ramírez, Daniel, et al.
Publicado: (2018)

A single dose of SAAVI MVA-C reboosts rhesus macaques after more than 3 years post DNA-MVA prime-boost vaccination
por: Chege, GK, et al.
Publicado: (2012)

Sequential administration of MVA-based vaccines and PD-1/PD-L1-blocking antibodies confers measurable benefits on tumor growth and survival: Preclinical studies with MVA-βGal and MVA-MUC1 (TG4010) in a murine tumor model
por: Remy-Ziller, Christelle, et al.
Publicado: (2017)

Deletion of Vaccinia Virus A40R Gene Improves the Immunogenicity of the HIV-1 Vaccine Candidate MVA-B
por: Pérez, Patricia, et al.
Publicado: (2020)

The Combined Expression of the Nonstructural Protein NS1 and the N-Terminal Half of NS2 (NS2(1-180)) by ChAdOx1 and MVA Confers Protection against Clinical Disease in Sheep upon Bluetongue Virus Challenge
por: Utrilla-Trigo, Sergio, et al.
Publicado: (2022)

Evidence for Env-V2 sieve effect in breakthrough SIV (MAC251) infections in rhesus monkeys vaccinated with Ad26/MVA and MVA/Ad26 constructs
por: Sina, S, et al.
Publicado: (2012)

Single-Molecule Study on Histone-Like Nucleoid-Structuring Protein (H-NS) Paralogue in Pseudomonas aeruginosa: MvaU Bears DNA Organization Mode Similarities to MvaT
por: Winardhi, Ricksen S., et al.
Publicado: (2014)

HIV-1 gp120 and Modified Vaccinia Virus Ankara (MVA) gp140 Boost Immunogens Increase Immunogenicity of a DNA/MVA HIV-1 Vaccine
por: Shen, Xiaoying, et al.
Publicado: (2017)

Immune Profiles Identification by Vaccinomics After MVA Immunization in Randomized Clinical Study
por: Sanchez, Jorge, et al.
Publicado: (2020)

MVA Vectored Vaccines Encoding Rift Valley Fever Virus Glycoproteins Protect Mice against Lethal Challenge in the Absence of Neutralizing Antibody Responses
por: López-Gil, Elena, et al.
Publicado: (2020)

The Type II restriction endonuclease MvaI has dual specificity
por: Stier, Ildikó, et al.
Publicado: (2010)

Excitation and voltage regulation for a 95 MVA surge-power generator
por: Bayer, K H, et al.
Publicado: (1972)

The foundations of a 95 MVA motor-generator set for pulsed duty
por: Probst, P H
Publicado: (1972)

Specification for a rectifier transformer (8MVA) for pulsed power supply
Publicado: (1978)

A novel genotype of MVA that efficiently replicates in single cell suspensions
por: Jordan, Ingo, et al.
Publicado: (2013)

Immunogenicity of ChAd63 + MVA ME-TRAP in Senegalese adults
por: Mensah, Victorine, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_3jcurmem9mqgsf9376flh2fdn6